Magnetic resonance imaging is a valuable tool to evaluate the therapeutic efficacy of burosumab in children with X-linked hypophosphatemia.

Volha V ZhukouskayaInès MannesCatherine ChaussainPeter KamenickỷChristelle AudrainAnne-Sophie LambertJérôme NevouxPhilippe WicartKarine BriotFederico Di RoccoSéverine TrabadoDominique PriéCarolina Di SommaAnnamaria ColaoCatherine AdamsbaumAnya RothenbuhlerAgnès Linglart

Published in: European journal of endocrinology (2021)

We suggest that MRI is a valuable and quantitative tool to evaluate the therapeutic response to burosumab. MRI could be an excellent alternative to standard bone radiographs for evaluation of the rachitic lesions in a clinical setting avoiding repeated exposition to ionizing radiation.

Keyphrases

magnetic resonance imaging
contrast enhanced
diffusion weighted imaging
computed tomography
young adults
magnetic resonance
high resolution
bone loss